
Athira Pharma, Inc. (ATHA)
$
3.91
+0.04 (1.02%)
Key metrics
Financial statements
Free cash flow per share
-13.2724
Market cap
17.8 Million
Price to sales ratio
0
Debt to equity
0.0340
Current ratio
9.6968
Income quality
1.3876
Average inventory
0
ROE
-1.0706
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company that focuses on developing small molecules aimed at restoring neuronal health and slowing neurodegradation. The company achieved a revenue of $0.00 indicating its niche market focus. Athira's lead product candidate, ATH-1017, is a blood-brain barrier-penetrating small molecule HGF/MET positive modulator currently undergoing LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for Alzheimer's disease treatment, as well as Phase 2 clinical trials for Parkinson's disease. In addition, the company has product candidates in the preclinical stage, including ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations, while also recording an income tax expense of $0.00 indicating its tax obligations. Furthermore, Athira Pharma recorded an operating income of -$100,902,000.00 reflecting its earnings from core operations, and earned an interest income of $3,962,000.00 showcasing its financial investments. Established in 2011 and headquartered in Bothell, Washington, Athira Pharma was formerly known as M3 Biotechnology, Inc., a name it adopted in April 2019. Athira Pharma's stock is affordable at $3.87 making it suitable for budget-conscious investors. The stock enjoys a high average trading volume of 31,568.00 indicating strong liquidity in the market. With a market capitalization of $15,420,598.00 the company is classified as a small-cap player, which allows for potential growth within the sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Athira belongs to the Healthcare sector, driving innovation and growth through its development of promising therapeutic candidates.
Investing in Athira Pharma, Inc. (ATHA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Athira Pharma, Inc. stock to fluctuate between $2.20 (low) and $6.09 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-12-16, Athira Pharma, Inc.'s market cap is $15,420,598, based on 3,943,887 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Athira Pharma, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Athira Pharma, Inc. (ATHA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATHA. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Athira Pharma, Inc.'s last stock split was 1:10 on 2025-09-18.
Revenue: $0 | EPS: -$25.20 | Growth: -18.45%.
Visit https://www.athira.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $16.65 (2021-11-12) | All-time low: $0.22 (2025-04-08).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

accessnewswire.com
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BRITISH COLUMBIA / ACCESS Newswire / December 15, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce that, further to its news releases of November 17, November 24 and December 9, 2025, the Company has closed the second tranche of its private placement financing (the "Offering") and has received proceeds of CDN $270,499.98 through the issuance of 150,000 flow-through units (the "FT Units") at CDN $0.07 per FT Unit and 4,333,333 non-flow-through units (the "NFT Units") at CDN $0.06 per NFT Unit. An aggregate of CDN $2,727,526.03 was raised in the first tranche of the Offering.

thenewswire.com
Vancouver, British Columbia – December 11, 2025 – TheNewswire - Generation Uranium Inc. (TSXV:GEN, OTCQB: GENRF) (the “Company” or “Generation”) is pleased to see Atha Energy's success in exploration in the Angikuni Basin located south of the Companies Yath Project. Atha has now reported multiple discoveries at the RIB target area on November 20 th and December 10, 2025. All exploration drill holes at the RIB zone intersected uranium mineralization, (Atha press release, Dec 10, 2025) with up to 5.55% U3O8. These discoveries are a clear demonstration of both the Angikuni Basin's uranium potential and also the hard work and effective exploration of the Atha Energy team.

accessnewswire.com
Maiden diamond drilling returns 4.33 g/t Au over 14.4m; geophysics defines large intrusive WHITE ROCK, BC / ACCESS Newswire / November 26, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project in Nevada. Mammoth Minerals Limited (ASX:M79) (formerly Firetail Resources Limited) has been aggressively exploring Excelsior, per its option agreement to earn an 80% interest in the project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see press releases dated June 2, 2025, and August 22, 2025).

accessnewswire.com
Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 31, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company"), is pleased to announce that, further to its press release dated October 21, 2025, the Company has filed its final short form prospectus (the "Prospectus") with the securities commissions in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and New Brunswick and been issued a receipt (the "Receipt") by the British Columbia Securities Commission, as principal regulator, in connection with the qualification of up to 18,838,752 units (the "Units") of the Company issuable upon the exercise or deemed exercise of 17,126,138 special warrants ("Special Warrants") of the Company issued in connection with its previously announced private placement.

accessnewswire.com
Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / ATHA Energy Corp. (TSX.V:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company"), is pleased to announce that, further to its press releases dated September 18, 2025 and August 11, 2025, the Company has filed its annual information form for the fiscal year ended December 31, 2024 (the "AIF"), and a preliminary short form prospectus (the "Prospectus") with the securities commissions in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and New Brunswick, in connection with the proposed qualification of up to 18,838,752 units (the "Units") of the Company issuable upon the exercise or deemed exercise of 17,126,138 special warrants ("Special Warrants") of the Company issued in connection with its previously announced private placement.

accessnewswire.com
VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company") announces that, as a result of a review by the British Columbia Securities Commission ("BCSC"), the Company is issuing the following news release to clarify its disclosure regarding the Angilak Project. The BCSC review identified certain deficiencies in the Company's prior technical disclosure, including the treatment of historical mineral resource estimates and the disclosure of an exploration target model.

accessnewswire.com
HIGHLIGHTS ATHA closes previously announced CAD $11.5 Million Over-Subscribed Bought Deal (See detail below, "Underwritten Private Placement"); First two drill holes completed at the RIB West Discovery successfully intersected uranium mineralization, including high-grade, over a strike length of ~340 m (Figure 2); Results represent the third new discovery of uranium mineralization - beyond the Lac 50 Deposit Trend - during the 2025 Angilak Exploration Program, within the Angikuni Basin along the 31 km RIB-Nine Iron Trend (Figure 1); RIB East Discovery is currently defined by eight mineralized drill holes, intersecting shallow uranium mineralization (7 million acres) in two of the world's most prominent basins for uranium discoveries - ATHA is well positioned to drive value. ATHA also holds a 10% carried interest in key Athabasca Basin exploration projects operated by NexGen Energy Ltd.

globenewswire.com
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira's issued and authorized common stock. Athira's stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company's Annual Meeting of Stockholders held on May 29, 2025.

accessnewswire.com
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / September 10, 2025 / ATHA Energy Corp. (TSX.V:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company"), as a result of a review by the British Columbia Securities Commission, the Company is issuing the following news release to clarify certain disclosure. The Company announces today that it has filed: (i) an updated technical report in respect of its CMB property located in Newfoundland and Labrador, Canada dated July 8, 2025 and effective June 14, 2025 entitled "NI 43-101 Technical Report, Central Mineral Belt Property, Newfoundland and Labrador, Canada" prepared by Stefan Kruse, Ph.D.

accessnewswire.com
EXCELSIOR SPRINGS FULLY FUNDED FOR 2025 DRILLING PROGRAM WHITE ROCK, BC / ACCESS Newswire / August 22, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to announce that, further to its news release dated June 2, 2025, Mammoth Minerals Limited (ASX:M79) (formerly, Firetail Resources Limited) ("Mammoth" or "M79") has exercised its option to be able to earn an 80% interest in Athena's Excelsior Springs project in Nevada, USA (the "Excelsior" project), effective August 19, 2025 (the "Exercise Date"). In consideration.
See all news